Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097466 | 0.88 | MAOB (0.44) | PPARGPPARDPPARALTB4RLTB4R2 | |
| SCHEMBL7064807 | 0.85 | MAPK1 (0.45) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL6098592 | 0.85 | PPARD (0.48) | PPARGPPARDPPARAMAOBMAOA | |
| SCHEMBL6099511 | 0.85 | MAOB (0.41) | PPARGPPARDPPARAMAOBMAOA | |
| SCHEMBL6098735 | 0.84 | BAZ2B (0.48) | PPARGPPARDPPARALTB4RLTB4R2 | |
| SCHEMBL6099720 | 0.80 | PPARD (0.50) | PPARGPPARDPPARAMAOBMAOA | |
| SCHEMBL6100670 | 0.80 | MAOB (0.43) | MAOBMAOASRD5A2 | |
| SCHEMBL6100791 | 0.79 | PPARD (0.44) | PPARGPPARDPPARAMAOBMAOA | |
| SCHEMBL6100606 | 0.77 | PPARD (0.46) | PPARGPPARDPPARAMAOBMAOA | |
| SCHEMBL6098776 | 0.76 | LTA4H (0.39) | PPARGPPARDPPARALTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | PPARG 476/4885PPARD 437/4885PPARA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.